IP Verse

Methods For Preventing Or Treating Allergy By Administering An Il-4R Antagonist - EP3506931B1

PatentPatent Analysis

EP3506931

REGENERON PHARMACEUTICALS
Application Number
EP17771619A
Filing Date
Aug 31, 2017
Status
Granted And Under Opposition
Jun 27, 2024
Grant Date
Jul 31, 2024
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP4252857B1
EP3889181B1
EP3460063B1

Bibliography

The patent EP3506931B1 was granted to Regeneron Pharmaceuticals on Jul 31, 2024 following the initial filing on Aug 31, 2017 under the application number EP17771619A . The current legal status of the patent is Granted And Under Opposition.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

BOULT WADE TENNANTApr 30, 2025ADMISSIBLE
HAMPTON KNOWLESApr 30, 2025ADMISSIBLE
SECERNAApr 30, 2025ADMISSIBLE
LUIGIApr 29, 2025ADMISSIBLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents